| TKI . | 1st Line of Treatment (n = 139) . | 2nd Line of Treatment (n = 38) . | 3rd Line of Treatment (n = 4) . | 4th Line of Treatment (n = 1) . | Total (n = 182) . | MTC (n = 100) . | DTC/PDTC (n = 82) . |
|---|---|---|---|---|---|---|---|
| Aflibercept | 1 (1%) | — | — | — | 1 (1%) | — | 1 (1%) |
| Cabozantinib | 10 (7%) | 1 (2%) | 1 (25%) | — | 12 (6%) | 12 (12%) | — |
| Lenvatinib | 6 (4%) | 3 (8%) | — | — | 9 (5%) | 3 (3%) | 6 (7%) |
| Motesanib | 11 (8%) | — | — | — | 11 (6%) | 9 (9%) | 2 (2%) |
| Sorafenib | 36 (26%) | 10 (26%) | — | — | 46 (25%) | 6 (6%) | 40 (50%) |
| Sunitinib | 5 (4%) | 12 (32%) | 3 (75%) | 1 (100%) | 21 (12%) | 6 (6%) | 15 (18%) |
| Vandetanib | 70 (50%) | 12 (32%) | — | — | 82 (45%) | 64 (64%) | 18 (22%) |
| TKI . | 1st Line of Treatment (n = 139) . | 2nd Line of Treatment (n = 38) . | 3rd Line of Treatment (n = 4) . | 4th Line of Treatment (n = 1) . | Total (n = 182) . | MTC (n = 100) . | DTC/PDTC (n = 82) . |
|---|---|---|---|---|---|---|---|
| Aflibercept | 1 (1%) | — | — | — | 1 (1%) | — | 1 (1%) |
| Cabozantinib | 10 (7%) | 1 (2%) | 1 (25%) | — | 12 (6%) | 12 (12%) | — |
| Lenvatinib | 6 (4%) | 3 (8%) | — | — | 9 (5%) | 3 (3%) | 6 (7%) |
| Motesanib | 11 (8%) | — | — | — | 11 (6%) | 9 (9%) | 2 (2%) |
| Sorafenib | 36 (26%) | 10 (26%) | — | — | 46 (25%) | 6 (6%) | 40 (50%) |
| Sunitinib | 5 (4%) | 12 (32%) | 3 (75%) | 1 (100%) | 21 (12%) | 6 (6%) | 15 (18%) |
| Vandetanib | 70 (50%) | 12 (32%) | — | — | 82 (45%) | 64 (64%) | 18 (22%) |
| TKI . | 1st Line of Treatment (n = 139) . | 2nd Line of Treatment (n = 38) . | 3rd Line of Treatment (n = 4) . | 4th Line of Treatment (n = 1) . | Total (n = 182) . | MTC (n = 100) . | DTC/PDTC (n = 82) . |
|---|---|---|---|---|---|---|---|
| Aflibercept | 1 (1%) | — | — | — | 1 (1%) | — | 1 (1%) |
| Cabozantinib | 10 (7%) | 1 (2%) | 1 (25%) | — | 12 (6%) | 12 (12%) | — |
| Lenvatinib | 6 (4%) | 3 (8%) | — | — | 9 (5%) | 3 (3%) | 6 (7%) |
| Motesanib | 11 (8%) | — | — | — | 11 (6%) | 9 (9%) | 2 (2%) |
| Sorafenib | 36 (26%) | 10 (26%) | — | — | 46 (25%) | 6 (6%) | 40 (50%) |
| Sunitinib | 5 (4%) | 12 (32%) | 3 (75%) | 1 (100%) | 21 (12%) | 6 (6%) | 15 (18%) |
| Vandetanib | 70 (50%) | 12 (32%) | — | — | 82 (45%) | 64 (64%) | 18 (22%) |
| TKI . | 1st Line of Treatment (n = 139) . | 2nd Line of Treatment (n = 38) . | 3rd Line of Treatment (n = 4) . | 4th Line of Treatment (n = 1) . | Total (n = 182) . | MTC (n = 100) . | DTC/PDTC (n = 82) . |
|---|---|---|---|---|---|---|---|
| Aflibercept | 1 (1%) | — | — | — | 1 (1%) | — | 1 (1%) |
| Cabozantinib | 10 (7%) | 1 (2%) | 1 (25%) | — | 12 (6%) | 12 (12%) | — |
| Lenvatinib | 6 (4%) | 3 (8%) | — | — | 9 (5%) | 3 (3%) | 6 (7%) |
| Motesanib | 11 (8%) | — | — | — | 11 (6%) | 9 (9%) | 2 (2%) |
| Sorafenib | 36 (26%) | 10 (26%) | — | — | 46 (25%) | 6 (6%) | 40 (50%) |
| Sunitinib | 5 (4%) | 12 (32%) | 3 (75%) | 1 (100%) | 21 (12%) | 6 (6%) | 15 (18%) |
| Vandetanib | 70 (50%) | 12 (32%) | — | — | 82 (45%) | 64 (64%) | 18 (22%) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
